MedTrace Logo

Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia

NCT00594737 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2012-06-04

No results posted yet for this study

Summary

Memantine has been approved for use in Alzheimer's disease. Its mechanism of action raises questions of whether it can also be effective for non-Alzheimer's dementias such as frontotemporal dementia (FTD), which currently has no disease-modifying treatment.

This is an open-label study to probe the effects of memantine in 15 outpatients diagnosed with FTD, as shown objectively by comparing PET scans performed before and after use of the medication. The specific type of PET scan, FDG-PET, allows the investigators to gauge the effects of memantine on cortical activity levels. The investigators hypothesize that subjects on memantine will show normalization of cortical metabolic activity.

Conditions

  • Frontotemporal Dementia

Interventions

DRUG

memantine hydrochloride

memantine hydrochloride oral tablets, 10mg po bid

Sponsors & Collaborators

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • Tiffany Chow, MD

    lead OTHER

Principal Investigators

  • Tiffany W Chow, MD · Rotman Research Institute at Baycrest, University of Toronto

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00594737 on ClinicalTrials.gov